Stellar Pharmaceuticals Inc.

Stellar Pharmaceuticals Inc.

March 29, 2005 18:01 ET

Stellar Pharmaceuticals Schedules Fourth Quarter And Year-End Financial Results And Conference Call


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: STELLAR PHARMACEUTICALS INC.

TSX VENTURE SYMBOL: SLX
OTC Bulletin Board SYMBOL: SLXCF

MARCH 29, 2005 - 18:01 ET

Stellar Pharmaceuticals Schedules Fourth Quarter And
Year-End Financial Results And Conference Call

LONDON, ONTARIO--(CCNMatthews - March 29, 2005) - Stellar
Pharmaceuticals, Inc., (OTCBB:SLXCF)(TSX VENTURE:SLX), a Canadian
pharmaceutical developer and marketer of high quality, cost-effective
products for select health care markets, today announced that it plans
to release its 2004 fourth quarter and year-end financial results prior
to the opening of the stock market on Thursday, March 31, 2005.
Management will conduct a conference call later that morning at 11:00
a.m. Eastern Time to discuss these results. Interested parties may
participate in the call by dialing 877-888-3490 (Domestic) or
416-695-5261 (International) approximately 10 minutes before the call is
scheduled to begin and ask to be connected to the Stellar
Pharmaceuticals Conference Call.

The call will also be simultaneously broadcast over the Internet. Those
interested in listening to the live webcast may do so by going to the
Company's website at www.stellarint.com or by going to
http://events.onlinebroadcasting.com/stellar/033105/index.php. Web
participants are encouraged to go to either website at least 15 minutes
prior to the start of the call to register, download and install any
necessary audio software. The online archive will be available
immediately after the live call and continue for approximately 30 days.

About Stellar Pharmaceuticals

Stellar Pharmaceuticals Inc. has developed and is marketing three
products in Canada based on its core polysaccharide technology:
NeoVisc®, for the treatment of osteoarthritis, Uracyst® and the
Uracyst® Test Kit, Stellar's patented technology for the diagnosis and
treatment of Interstitial Cystitis (IC), an inflammatory disease of the
urinary bladder wall. Stellar also has in-licensing agreements for
Skelite™, a proprietary synthetic bone-grafting product and NMP22®
BladderChek®, a proteomics-based diagnostic test for the diagnosis and
monitoring of bladder cancer which are expected to positively impact
sales in 2005.

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Readers are cautioned
not to place undue reliance on these forward-looking statements. Actual
results may differ materially from those indicated by these
forward-looking statements as a result of risks and uncertainties
impacting the Company's business including increased competition; the
ability of the Company to expand its operations, to attract and retain
qualified professionals, technological obsolescence; general economic
conditions; and other risks detailed time to time in the Company's
filings.


-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Stellar Pharmaceuticals Inc.
    Peter Riehl
    President & CEO
    (800) 639-0643 or (519) 434-1540
    or
    Stellar Pharmaceuticals Inc.
    Arnold Tenney
    Cell (416) 587-3200
    or
    The Equity Group Inc.
    Devin Sullivan
    (212) 836-9608
    dsullivan@equityny.com
    or
    The Equity Group Inc.
    Adam Prior
    (212) 836-9606
    aprior@equityny.com
    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this release.